Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population
To compare health-related quality of life (HRQoL) between hepatitis C patients who achieve sustained virological response (SVR) to direct-acting antivirals and a sex- and age-paired sample of the general population.
HRQoL was evaluated in patients recruited in Navarre, Spain, from May 2016 to April 2017 at baseline and after SVR, using the EQ-5D-5L questionnaire. Both results were compared to those of general population of the same sex and age obtained from the 2011/12 National Health Survey in Spain. Observed/expected (O/E) ratios for health dimensions and differences between O-E in EQ-5D utility and visual analogical scale (VAS) scores were calculated.
206 patients were studied. Before treatment, patients had more problems than the general population in every domain of EQ-5D-5L, except in self-care dimension (O/E = 1.1). After SVR, patients continued having more limitation, especially for usual activities (O/E = 3.1), anxiety/depression (O/E = 2.8) and EQ-5D utility (− 0.086, p < 0.001); however, differences in VAS score between patients and general population disappeared (74.8 vs 76.5, p = 0.210). F0–F1 patients with SVR had minor differences with the general population in EQ-5D-5L dimensions, utility and VAS score. Although cirrhotic patients also reduced that difference, they still had worse HRQoL, especially in usual activities, self-care, EQ-5D utility (− 0.152, p < 0.001) and VAS score (− 8.5, p = 0.005).
HRQoL of chronic hepatitis C patients remains lower than that of the general population despite viral clearance, with primary problems in usual activities and anxiety/depression. Knowledge of these on-going problems despite cure serves to guide healthcare interventions and patient’s follow-up.
KeywordsHealth-related quality of life Quality of life Hepatitis C Direct-acting antiviral EQ-5D Population norms
This work is part of the EIPT-VHC project, which was supported by the Spanish Ministry of Health and by the Carlos III Health Institute in the context of the “Strategic Plan for Tackling Hepatitis C in the Spanish National Health System”. Regina Juanbeltz and Jesús Castilla have received funding from the Carlos III Institute of Health with the European Regional Development Fund (CM17/00095, INT17/00066). These institutions did not have any role in the research and writing of this manuscript.
This work is part of the EIPT-VHC project, which was supported by the Spanish Ministry of Health and by the Carlos III Health Institute in the context of the “Strategic Plan for Tackling Hepatitis C in the Spanish National Health System”. These institutions did not have any role in the research and writing of this manuscript.
Compliance with ethical standards
Conflict of interest
RJ and JC have received research grants from Carlos III Institute of Health with the European Regional Development Fund, during the conduct of the study (CM17/00095, INT17/00066). IMB, AO, MS and RSM declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Juanbeltz, R., Zozaya, J. M., Reparaz, J., Castilla, J., Sarobe, M. T., Uriz Otano, J. I., et al. (2017). Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. Anales del Sistema Sanitario de Navarra, 40(1), 57–66.Google Scholar
- 5.Kouris, G., Hydery, T., Greenwood, B. C., Lavitas, P., Price, M., Clements, K., et al. (2018). Effectiveness of Ledipasvir/Sofosbuvir and predictors of treatment failure in members with hepatitis C genotype 1 infection: A retrospective cohort study in a medicaid population. Journal of Managed Care and Specialty Pharmacy, 24(7), 591–597.CrossRefGoogle Scholar
- 6.Honer Zu Siederdissen, C., Buggisch, P., Boker, K., Schott, E., Klinker, H., Pathil, A., et al. (2018). Treatment of hepatitis C genotype 1 infection in Germany: Effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterology Journal, 6(2), 213–224.CrossRefGoogle Scholar
- 18.de Sanidad, M., Servicios Sociales e Igualdad. Encuesta Nacional de Salud de España. (2016). Retrieved May 22, 2018, from https://www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/home.htm.
- 21.EuroQol Group. Retrieved September 3, 2018, from https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/crosswalk-index-value-calculator/.
- 23.Rothman, K., & Boice, J. D. (1979). Epidemiologic analysis with a programmable calculator. Washington, DC: U.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health.Google Scholar
- 24.Dean, A. G., Sullivan, K. M., Soe, M. M.. OpenEpi: Open source epidemiologic statistics for public health. (2013). Retrieved December 31, 2018, from https://www.OpenEpi.com.
- 26.Fotos, N. V., Elefsiniotis, I., Patelarou, A., Giakoumidakis, K., Patelarou, E., Kouros, A., et al. (2018). Psychological disorders and quality of life among patients with chronic viral hepatitis: A single-center cross-sectional study with pair-matched healthy controls. Gastroenterology Nursing, 41(3), 206–218.CrossRefGoogle Scholar
- 29.de Sanidad, M. Servicios Sociales e Igualdad. (2017). Plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad. Retrieved June 25, 2018, from https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/home.htm.
- 30.Younossi, Z. M., Stepanova, M., Feld, J., Zeuzem, S., Sulkowski, M., Foster, G. R., et al. (2017). Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clinical Gastroenterology and Hepatology, 15(3), 421–430.e6.CrossRefGoogle Scholar
- 31.Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Review of Gastroenterol and Hepatology, 11(3), 259–268.Google Scholar
- 37.Buchanan-Hughes, A. M., Buti, M., Hanman, K., Langford, B., Wright, M., & Eddowes, L. A. (2018). Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: A systematic literature review and meta-analysis. Quality of Life Research. https://doi.org/10.1007/s11136-018-1992-3.Google Scholar